InterVenn Biosciences operates a proprietary glycoproteomics biomarker interrogation platform that combines mass spectrometry with AI to enable next-generation precision medicine. The platform has been used to develop 16 clinical use cases across oncology and other indications. The company is developing Dawn™, a liquid-biopsy assay for predicting response to immune checkpoint inhibitors, which it planned to commercialize in 2022. With new funding, InterVenn intends to accelerate development and commercialization of Dawn and to expand investment in glycoproteomics-based liquid biopsy solutions across the oncology spectrum (screening through therapy response monitoring) and into non-oncology applications. The financing will also enable the company to expand its partnership ecosystem to accelerate development and commercialization of new clinical solutions and broaden insights into new biomarkers and therapies. InterVenn is based in South San Francisco, California. InterVenn develops a proprietary glycoproteomic biomarker‑interrogation platform that combines mass spectrometry with an AI neural network (PiP™) and powers the Vista™ research product. Vista™ provides application‑specific disease classifier panels across more than a dozen oncology indications and has been used to predict response to checkpoint‑inhibitor treatment. The company is commercializing a High‑Throughput‑Glycoproteomic LDT for ovarian cancer and is enrolling patients in V.O.C.A.L.™, a multicenter international trial whose interim results show the InterVenn test outperforming CA 125 in specificity and sensitivity. InterVenn plans to use new funds to scale commercialization of the ovarian diagnostic, service increasing partnership platform demand, and accelerate development of immuno‑oncology treatment‑response and colorectal cancer indications. The company is headquartered in South San Francisco and is commissioning new office and laboratory space there. Leadership additions include John Leite, Ph.D., as Chief Business Officer and David Michael of Anzu Partners joining the board. InterVenn BioSciences develops an AI-driven mass spectrometry glycoproteomics platform to rapidly characterize post-translational modifications and identify clinically relevant biomarkers. The company leverages mass spectrometry, high-resolution PTM characterization, and artificial intelligence to streamline glycoproteomics workflows and improve reproducibility across sample collection, processing, and instrument ingestion. Its first product is a blood-based ovarian cancer diagnostic that is undergoing analytical and clinical validation. Once validation and regulatory processes are completed, InterVenn plans to offer the test as a laboratory diagnostic. The platform is positioned for additional applications across cancers, autoimmunity, fibrosis, and neurodegeneration. The company is headquartered in Redwood City, California.

Total raised

$244M

Funding rounds

3

Latest round

Series C

Latest activity

Aug 2021